<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712669</url>
  </required_header>
  <id_info>
    <org_study_id>RVT-1201-2002 / ELEVATE 2</org_study_id>
    <nct_id>NCT04712669</nct_id>
  </id_info>
  <brief_title>A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2)</brief_title>
  <official_title>A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altavant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altavant Sciences GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in&#xD;
      pulmonary arterial hypertension (PAH) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rodatristat Ethyl is a peripherally restricted TPH inhibitor being studied as a potential&#xD;
      treatment for PAH. This dose-ranging, randomized, double-blind, placebo-controlled,&#xD;
      multicenter study will evaluate the effect of Rodatristat Ethyl from baseline on pulmonary&#xD;
      vascular resistance as measured at right heart catheterization.&#xD;
&#xD;
      Patients will be enrolled into a main study with an option to enroll into an open label&#xD;
      extension.&#xD;
&#xD;
      The study is expected to enroll patients in the USA, Canada and Europe.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Following screening assessments, Patients will be enrolled into 1 of 3 treatment arms in a 1:1:1 randomization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of pulmonary vascular resistance as measured by right heart catheterization</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of cardiac index (CI)</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of mean pulmonary artery pressure (mPAP)</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of mean mixed venous oxygen saturation (SvO2)</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of pulmonary artery compliance (PAC)</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first occurrence of a clinical worsening event (TTCW)</measure>
    <time_frame>From initiation to Week 24</time_frame>
    <description>Time to Clinical Worsening (TTCW) defined as the first occurrence of: 1. Death from any cause, 2. Hospitalization for worsening PAH (any hospitalization for worsening PAH, lung or heart and lung transplantation, atrial septostomy, or initiation of parenteral prostanoid therapy), 3. Disease progression defined as a decrease of more than 15% from Baseline in the 6-minute walk distance (6MWD) combined with World Health Organization (WHO) Functional Class (FC) III or IV symptoms at 2 consecutive visits separated by at least 14 days (adjudicated)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline in WHO FC World Health Organization (WHO) Functional Class (FC)</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 6MWD</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) levels</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in of right atrial size by echocardiogram</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the tricuspid annular systolic velocity by echocardiogram</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the tricuspid annular plane systolic excursion (TAPSE) by echocardiogram</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the RV fractional area change by echocardiogram</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline in the Pulmonary Arterial Hypertension Symptoms and Impact Questionnaire (PAH SYMPACT) Score</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline in the Registry to Evaluate Early and Long Term PAH Disease Management (REVEAL) Lite 2 score</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma and urine 5-hydroxyindoleacetic acid (5-HIAA)</measure>
    <time_frame>From initiation to Week 24</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to Clinical Improvement (TTCI)</measure>
    <time_frame>From initiation to Week 24</time_frame>
    <description>A &gt; 10% increase in 6MWD or 30 meters AND an improvement to or maintenance of WHO FC II symptomatology, in the absence of a deterioration in clinical condition or death during the 24 weeks of the Main Study</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline on the following actigraphy endpoints:</measure>
    <time_frame>From initiation to Week 24</time_frame>
    <description>1. Light to vigorous activity/day, 2. Moderate to vigorous activity/day, 3.Total movement/day, 4.Best 6-minute walk effort</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Rodatristat Ethyl 300 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rodatristat ethyl 300 mg tablet BID + standard of care medication(s) taken for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rodatristat Ethyl 600 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rodatristat ethyl 600 mg tablet BID + standard of care medication(s) taken for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablet + standard of care medication(s) taken for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rodatristat Ethyl 300 mg tablet</intervention_name>
    <description>Rodatristat ethyl is a tryptophan hydroxylase (TPH) inhibitor designed to block peripheral serotonin production.</description>
    <arm_group_label>Rodatristat Ethyl 300 mg BID</arm_group_label>
    <arm_group_label>Rodatristat Ethyl 600 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive pill manufactured to mimic rodatristat ethyl</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Rodatristat Ethyl 300 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female 18 years or older&#xD;
&#xD;
          -  Body Mass Index (BMI) 18kg/m2 to 38kg/m2&#xD;
&#xD;
          -  Symptomatic PAH belonging to WHO Group 1 on a stable treatment regimen with one or&#xD;
             more approved PAH treatments&#xD;
&#xD;
          -  PAH defined as mean pulmonary artery pressure ≥ 20 mmHg during right heart&#xD;
             catheterization performed at rest&#xD;
&#xD;
          -  FEV1 ≥ 60 % of predicted normal, FEV1:FVC ratio ≥ 0.70 or TLC ≥ 70% of predicted&#xD;
             normal&#xD;
&#xD;
          -  WHO FC II or III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  WHO Pulmonary Hypertension (PH) Group 2 - 5&#xD;
&#xD;
          -  PAH associated with significant venous or capillary involvement (PCWP &gt; 15 mmHg),&#xD;
             pulmonary capillary hemangiomatosis, portal hypertension, or unrepaired congenital&#xD;
             heart defects (CHD))&#xD;
&#xD;
          -  Three or more risk factors for left ventricular disease; BMI ≥ 30 kg/m^2, diagnosis of&#xD;
             essential hypertension that is actively treated, diabetes mellitus, history of&#xD;
             significant coronary artery disease, atrial fibrillation, and/or left atrial volume&#xD;
             index &gt; 41 mL/m^2&#xD;
&#xD;
          -  Known genetic hypertrophic cardiomyopathy, or cardiac sarcoidosis or amyloidosis&#xD;
&#xD;
          -  The patient has a history of, or currently has, a constrictive cardiomyopathy&#xD;
&#xD;
          -  Known history of any LVEF &lt; 40% by echocardiogram within 3 years of randomization&#xD;
&#xD;
          -  Hemodynamically significant valvular heart disease&#xD;
&#xD;
          -  Patient severely disabled and unable to complete the study&#xD;
&#xD;
          -  End stage renal disease or severe liver disease&#xD;
&#xD;
          -  Known congenital long QT syndrome (LQTS) or known family history of LQTS&#xD;
&#xD;
          -  Depression that is currently rated as severe or recent suicidal behavior or active&#xD;
             suicidal ideation with intent to act&#xD;
&#xD;
          -  Uncontrolled arterial hypertension or hypotension&#xD;
&#xD;
          -  Patients currently taking one or more drugs known to prolong the QT interval and which&#xD;
             are clearly associated with a known risk of Torsades de Pointe&#xD;
&#xD;
          -  QTcF interval &gt; 450 ms for males or &gt; 470 ms for females&#xD;
&#xD;
          -  Any ECG or clinical laboratory abnormality which precludes safe participation in the&#xD;
             study in the opinion of the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Watiri Kamau-Kelley</last_name>
    <phone>+1-408-300-3316</phone>
    <email>watiri@altavant.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Howard Lazarus, MD</last_name>
    <phone>+1-203-297-5374</phone>
    <email>howard.lazarus@altavant.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Feldman, MD</last_name>
      <email>jpfeldman1@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Namita Sood, MD</last_name>
      <email>nsood@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Badesch, MD</last_name>
      <email>david.badesch@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mardi Gomberg-Maitland, MD</last_name>
      <email>mgomberg@mfa.gwu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Spikes, MD</last_name>
      <email>lspikes@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Hill, MD</last_name>
      <email>nhill@tuftsmedicalcenter.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murali Chakinala, MD</last_name>
      <email>chakinalam@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brown University - Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Ventetuolo, MD</last_name>
      <email>corey_ventetuolo@brown.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Chin, MD</last_name>
      <email>kelly.chin@utsouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

